What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Rimegepant demonstrated a clear clinical advantage over placebo in reducing pain at 2 hours, as evidenced by three double-blind RCTs (BHV3000-301, BHV3000-302, and BHV3000-303) with a total sample size of 3,507 participants. The trials showed significant improvements in primary outcomes, indicating a strong therapeutic impact.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for rimegepant fall below NICE’s acceptable thresholds, with the committee’s preferred ICER ranging between £15,000 and £30,000 per QALY gained. This indicates a strong economic value proposition for the treatment.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests moderate improvements in HRQoL for patients using rimegepant, as it addresses debilitating migraine symptoms that significantly affect daily functioning. However, specific validated tools measuring HRQoL were not detailed in the document.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Rimegepant has a very good safety profile, with adverse events reported as mild to moderate and low rates of severe or serious events. This favorable safety profile supports its use as an acute treatment for migraine.
Was the drug compared against what payers expect? — Comparator Selection
The clinical effectiveness of rimegepant was compared against placebo, which is appropriate given the context of acute migraine treatment. The committee agreed that placebo represented best supportive care, making it a suitable comparator.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a diverse population of adults with moderate-to-severe migraine attacks, although there were concerns about the generalizability to chronic migraine patients. The committee acknowledged the importance of considering subgroups, particularly those who cannot tolerate triptans.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Rimegepant can be integrated into existing care pathways with minor adjustments, as it is intended for patients who have already tried other treatments. The committee noted that it fits well within the current treatment landscape for acute migraine.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of rimegepant is manageable, aligning with Healthcare planning. The committee concluded that the treatment is resource-efficient, with minimal additional costs expected for its implementation.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by multiple RCTs with a low risk of bias, although there were some limitations regarding subgroup analyses. The inclusion of real-world data would further strengthen the robustness of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the generalizability of trial results, the committee found the overall context supportive of rimegepant’s use. The treatment addresses a significant unmet need in migraine management.
